Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's foreca

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued a

Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule preci

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leve

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidan

Bank of America Corp DE grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 10.9% in the

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% fr

Amundi raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 2,445.3% in the first quart

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweigh

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweig

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) on Monday reported better-than-expected second-quarter sales

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. A

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and rais

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the a

Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on ben

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the

Wall Street analysts change outlook on top stocks. For detailed ratings, upgrades/downgrades, see an

Canaccord Genuity analyst Gary Nachman initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) w

Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Deutsche Bank analyst Gregg Gilbert maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and r

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in po

New late-breaking data presentations underscore Jazz's significant progress in advancing holisti

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced top-line results from the Phase 3 LAGOON tria

Jazz Pharma (JAZZ) revenue growth driven by Ziihera adoption as 1L treatment for HER2+ GEA, says Bof

Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst r

B of A Securities analyst Jason Gerberry maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will present 21 abstracts, i

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Bernstein analyst Jeffrey Walch initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a M

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweig

UBS analyst Ashwani Verma upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Neutral to Buy and rai

The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zani

TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperfor

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a